Cost of Revenue Trends: Bristol-Myers Squibb Company vs Amphastar Pharmaceuticals, Inc.

Pharma Giants' Cost Trends: A Decade of Financial Insights

__timestampAmphastar Pharmaceuticals, Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 20141592050003932000000
Thursday, January 1, 20151741720003909000000
Friday, January 1, 20161509760004946000000
Sunday, January 1, 20171493800006066000000
Monday, January 1, 20181876810006547000000
Tuesday, January 1, 20191904340008078000000
Wednesday, January 1, 202020650600011773000000
Friday, January 1, 20212380290009940000000
Saturday, January 1, 202225012700010137000000
Sunday, January 1, 202329327400010693000000
Monday, January 1, 202411949000000
Loading chart...

Unleashing the power of data

Cost of Revenue Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Bristol-Myers Squibb Company and Amphastar Pharmaceuticals, Inc. have shown distinct cost of revenue trends. Bristol-Myers Squibb, a titan in the industry, saw its cost of revenue grow by approximately 172%, peaking in 2020. This surge reflects its aggressive expansion and investment in research and development. In contrast, Amphastar Pharmaceuticals, a smaller player, experienced a more modest increase of around 84% over the same period. This steady growth highlights its strategic focus on niche markets and cost efficiency. The data reveals a fascinating narrative of how two companies navigate financial challenges and opportunities in a competitive landscape. As the pharmaceutical sector continues to innovate, these trends offer valuable insights into the financial strategies of industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025